{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-017058","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.188462+00:00","generated_at":"2026-06-01T22:48:39.915115+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY","bullets":["Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.","ADHD Portfolio net revenue up 49% to $12.3M; Rx gross margin improved to 74%.","Consumer Health net revenue down 56% to $4.0M; wind-down continues as planned.","TTM companywide adjusted EBITDA positive $15.4M; Rx Business TTM adjusted EBITDA $17.1M.","Cash $19.8M; manufacturing transition expected to improve margins."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-017058","json":"https://secwatch.observer/filing/0001437749-24-017058.json","markdown":"https://secwatch.observer/filing/0001437749-24-017058.md","text":"https://secwatch.observer/filing/0001437749-24-017058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/0001437749-24-017058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/aytu20240223_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:48:39.915115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2f7833d61d27d94c74bc114df161d136f6ca9b6","claim":"AYTU BIOPHARMA, INC reported fiscal 2024 third quarter results: revenue $18.0 million, net income $2.9 million, EPS $0.52 per share.","evidence_excerpt":"on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter. ​ Q3 2024 Highlights ● Consolidated net revenue was $18.0 million versus $22.7 million in the prior year period and reflects the Company’s continued planned wind down of its Consumer Health Segment. ● ADHD Portfolio (Adzenys XR-ODT® and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924017058/0001437749-24-017058-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2024 third quarter"},{"label":"Revenue","value":"$18.0 million"},{"label":"Net income","value":"$2.9 million"},{"label":"EPS","value":"$0.52 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}